Language and behavioral outcomes of treatment with pulse-dose prednisone for electrical status epilepticus in sleep (ESES).


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
05 2019
Historique:
received: 04 12 2018
revised: 17 02 2019
accepted: 17 02 2019
pubmed: 22 3 2019
medline: 3 7 2020
entrez: 22 3 2019
Statut: ppublish

Résumé

Few studies have examined treatment response in electrical status epilepticus in sleep (ESES), and fewer still have evaluated the effect of corticosteroid treatment employing a pulse-dose regimen. The aim of this study was to examine the effectiveness of pulse-dose prednisone in treating language and behavioral disturbances that often accompany ESES. The sample included 17 patients age 5 to 10 years at time of baseline electroencephalogram (EEG) and neuropsychological assessments. For all patients, focal, multifocal, or generalized spike and wave activity occupied greater than 50% of the nonrapid eye movement (REM) sleep record. Patients were seen for follow-up EEG recording and neuropsychological testing with an average of 10 months following initiation of pulse-dose prednisone. Improvement in language or behavior was examined in relation to resolution of ESES on EEG, age at seizure onset and treatment, duration of ESES, duration of treatment, lesional versus nonlesional epilepsy, history of language or behavioral regression, seizure control at follow-up, and intelligence quotient (IQ). With the exception of a greater likelihood of patients with low IQ to demonstrate improvement in language or behavior, improvement was seen in most patients, irrespective of ESES or other factors.

Identifiants

pubmed: 30897536
pii: S1525-5050(18)30955-7
doi: 10.1016/j.yebeh.2019.02.016
pii:
doi:

Substances chimiques

Glucocorticoids 0
Prednisone VB0R961HZT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

93-99

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Ann Hempel (A)

Minnesota Epilepsy Group, P.A., St. Paul, Minnesota, USA. Electronic address: ahempel@mnepilepsy.net.

Michael Frost (M)

Minnesota Epilepsy Group, P.A., St. Paul, Minnesota, USA; Children's Hospitals and Clinics of Minnesota, St. Paul, Minnesota, USA.

Nitin Agarwal (N)

Minnesota Epilepsy Group, P.A., St. Paul, Minnesota, USA; Children's Hospitals and Clinics of Minnesota, St. Paul, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH